Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis

International Journal of Cancer

Volumn 141, Issue 5, 2017, Pages 1029-1041

  Xian, Miao ^a   Cao, Handi ^a   Cao, Ji ^a   Shao, Xuejing ^a   Zhu, Difeng ^a,b   Zhang, Ning ^c   Huang, Ping ^d   Li, Weixu ^c   Yang, Bo ^a   Ying, Meidan ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

adriamycin; bortezomib; CHOP; osteosarcoma; reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ACTIVATING TRANSCRIPTION FACTOR 4; BORTEZOMIB; DOXORUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; PHOSPHO INITIATION FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATF4 PROTEIN, HUMAN; DDIT3 PROTEIN, HUMAN; INITIATION FACTOR 2; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIZATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; ANIMAL; BONE TUMOR; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; BORTEZOMIB; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; EUKARYOTIC INITIATION FACTOR-2; FLOW CYTOMETRY; HUMANS; MICE; MICE, NUDE; OSTEOSARCOMA; PROTEASOME INHIBITORS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020117637     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30792     Document Type: Article

References (48)

1. Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett 2016;370:268–74.
2. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer 2008;112:416–32.
3. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008;7:3461–9.
4. Xu H, Niu X, Zhang Q, et al. Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol Lett 2011;2:773–8.
5. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460–70.
6. Orhan B. Doxorubicin cardiotoxicity: growing importance. J Clin Oncol 1999;17:2294–6.
7. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23559–68.
8. Buondonno I, Gazzano E, Jean SR, et al. Mitochondria-targeted doxorubicin: a new therapeutic strategy against doxorubicin-resistant osteosarcoma. Mol Cancer Ther 2016; 15:2640–52.
9. Kim DS, Woo ER, Chae SW, et al. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci 2007;80:314–23.
10. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837–46.
11. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007;23:15–25.
12. Tsang WP, Chau SP, Kong SK, et al. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 2003;73:2047–58.
13. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?. Antioxid Redox Signal 2007;9:2277–93.
14. Xue X, Piao JH, Nakajima A, et al. Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem 2005;280:33917–25.
15. Yokouchi M, Hiramatsu N, Hayakawa K, et al. Involvement of selective reactive oxygen species upstream of proapoptotic branches of unfolded protein response. J Biol Chem 2008;283:4252–60.
16. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012;13:89–102.
17. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291–4.
18. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009;152:467–78.
19. Pandit B, Gartel AL. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PLoS One 2011;6:e17110.
20. Raedler L. Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma. Am Health Drug Benefits 2015;8:135–40.
21. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–76.
22. Landis-Piwowar KR, Milacic V, Chen D, et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Update 2006;9:263–73.
23. Hui KF, Lam BH, Ho DN, et al. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther 2013;12:747–58.
24. Shapovalov Y, Benavidez D, Zuch D, et al. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 2010;127:67–76.
25. Schonthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 2013;85:653–66.
26. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7:1013–30.
27. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381–9.
28. Zhang L, Zhou Q, Zhang N, et al. E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARalpha. Cell Cycle 2014;13:1277–87.
29. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112–6.
30. Cao J, Wang Y, Dong R, et al. Hypoxia-induced WSB1 promotes the metastatic potential of osteosarcoma cells. Cancer Res 2015;75:4839–51.
31. Ying M, Zhou X, Zhong L, et al. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARalpha/STAT1 axis. Mol Cancer Ther 2013;12:195–206.
32. Zhu H, Ding WJ, Wu R, et al. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 2010;28:23–32.
33. Cao J, Xu D, Wang D, et al. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009;47:536–47.
34. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15–31.
35. Sparreboom A, Planting AS, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drugs 1999;10:719–28.
36. Leveque D, Carvalho MC, Maloisel F. Review. Clinical pharmacokinetics of bortezomib. In Vivo 2007;21:273–8.
37. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998;94:695–8.
38. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579–91.
39. Shen K, Xie J, Wang H, et al. Cambogin induces caspase-independent apoptosis through the ROS/JNK pathway and epigenetic regulation in breast cancer cells. Mol Cancer Ther 2015;14:1738–49.
40. Kuznetsov JN, Leclerc GJ, Leclerc GM, et al. AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 2011;10:437–47.
41. Quan Z, Gu J, Dong P, et al. Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to cirsimaritin-induced apoptosis in human gallbladder carcinoma GBC-SD cells. Cancer Lett 2010;295:252–9.
42. Kong Q, Lillehei KO. Antioxidant inhibitors for cancer therapy. Med Hypotheses 1998;51:405–9.
43. Sung B, Ravindran J, Prasad S, et al. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 2010;285:35418–27.
44. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;67:471–80.
45. Roccaro AM, Hideshima T, Richardson PG, et al. Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006;7:441–8.
46. Fels DR, Ye JB, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 2008;68:9323–30.
47. Fribley A, Zeng QH, Wang CY. Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695–704.
48. Nawrocki ST, Carew JS, Dunner K, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510–9.